Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561294 | 0.86 | KDM4E (0.67) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL18748437 | 0.86 | ACKR3 (0.48) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL17161708 | 0.80 | MEN1 (0.62) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL31248348 | 0.79 | KMT2A (0.73) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL17117491 | 0.78 | MEN1 (0.84) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL14025827 | 0.77 | KDM4E (0.59) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL13895390 | 0.77 | MEN1 (0.57) | MEN1KMT2ARAB9AKDM4ETP53 | |
| SCHEMBL17117334 | 0.75 | KMT2A (0.85) | MEN1KMT2ARAB9AKDM4EHPGD | |
| SCHEMBL12864706 | 0.74 | GAA (0.60) | MEN1KMT2AKDM4ETP53HPGD | |
| SCHEMBL304452 | 0.72 | RAB9A (0.55) | MEN1KMT2ARAB9AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | MEN1 2161/4885KMT2A 4371/4885RAB9A 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.